德国高剂量与标准剂量流感疫苗接种率比较
该回顾性研究利用IQVIA疫苗分析数据,分析2021-2022至2023-2024流感季德国≥60岁人群流感疫苗接种覆盖率及高剂量疫苗占比。结果显示接种率仍远低于国家目标,但高剂量疫苗占比显著上升至2023-2024季的92.4%,表明优先推荐逐渐被遵循,医生和患者接受度高。
要点
- 德国≥60岁人群流感疫苗接种率仍远低于国家目标。
- 高剂量流感疫苗占比显著上升,2023-2024季达92.4%。
- 优先推荐高剂量疫苗在医生和患者中接受度高。
核心结论
- 德国≥60岁人群流感疫苗接种覆盖率仍远低于国家目标,但高剂量疫苗占比显著上升,优先推荐逐渐被遵循。
研究设计与样本
- 回顾性研究,使用IQVIA™ Vaccine Analyzer数据,覆盖2021-2022至2023-2024流感季,分析≥60岁人群按个体和诊所特征分层的接种覆盖率及高剂量疫苗比例。
主要发现
- 流感疫苗接种覆盖率在德国老年人群中仍远低于国家目标。
- 高剂量疫苗接种比例显著上升,2023-2024季达到92.4%。
- 结果表明医生和患者对高剂量疫苗接受度高。
关键数值与推荐
- 2021年德国当局引入针对≥60岁成人的灭活四价高剂量流感疫苗优先推荐。
- 高剂量疫苗比例在2023-2024季升至92.4%。
临床怎么用
- 在≥60岁成人中优先推荐高剂量流感疫苗,可提高接种接受度。
- 需关注并提升老年人群流感疫苗总体接种覆盖率以达国家目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2021, German authorities introduced a preferential recommendation for inactivated quadrivalent high-dose (HD) influenza vaccines for adults aged 60 years and older. This recommendation was motivated by randomized and observational studies showing higher efficacy and effectiveness compared to standard-dose (SD) influenza vaccines in older adults. It is unknown to which extent this recommendation was followed. MATERIAL AND METHODS: This retrospective study uses IQVIA™ Vaccine Analyzer (VA) data from the 2021-2022 to 2023-2024 influenza seasons to examine vaccination coverage rates and proportions of HD among administered influenza vaccines in age group ≥60 years stratified by different individual-level and practice-level characteristics. RESULTS: Influenza vaccination coverage rates in the older German population remain far below national targets. However, the proportion of HD vaccinations increased significantly up to 92.4 % in 2023-2024, implying that the preferential recommendation was increasingly followed. Overall, our results indicate high acceptance of HD vaccines among physicians and patients.
引用
- Meyer AC, Braegelmann K, Orozco-Ruiz X, et al. Comparing uptake of high-dose and standard-dose influenza vaccination at the practice and patient level in Germany. Vaccine. 2025. PMID: 41360028. doi:10.1016/j.vaccine.2025.128075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。